Nature Search

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

In this work, Planas et al. report that Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 escape neutralization from monoclonal antibodies, and sera from vaccinated individuals with or without Omicron BA.1/2 or BA.5 breakthrough infection.

Delphine Planas
Timothée Bruel
Olivier Schwartz
ResearchOpen Access14 Feb 2023
Nature Communications

Volume: 14, P: 1-11
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

SARS-CoV-2 evolved into several sublineages harboring different mutations in spike. Here, the authors isolate and characterize nine SARS-CoV-2 variants and show that EG.5.1.3 has highest fitness in nasal epithelial cells, while JN.1 shows lower affinity to ACE2 and higher immune evasion compared to BA.2.86.1.

Delphine Planas
Isabelle Staropoli
Olivier Schwartz
ResearchOpen Access13 Mar 2024
Nature Communications

Volume: 15, P: 1-17
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Therapeutic antibodies, and sera from immunocompromised individuals prophylactically treated with therapeutic antibodies, differ in neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, which could have implications for pre-exposure and post-exposure treatment.

Timothée Bruel
Jérôme Hadjadj
Olivier Schwartz
Research23 Mar 2022
Nature Medicine

Volume: 28, P: 1297-1302
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

The SARS-CoV-2 Delta variant partially evades neutralization by several monoclonal antibodies and by sera from individuals who have had COVID-19, but two doses of anti-COVID-19 vaccines still generate a strong neutralizing response.

Delphine Planas
David Veyer
Olivier Schwartz
Research08 Jul 2021
Nature

Volume: 596, P: 276-280
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Sera from convalescent individuals with coronavirus disease 2019 and from individuals vaccinated with BNT162b2 have reduced ability to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351, but antibody potency against the variants increases after two vaccine doses.

Delphine Planas
Timothée Bruel
Olivier Schwartz
Research26 Mar 2021
Nature Medicine

Volume: 27, P: 917-924
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

An isolate of the Omicron variant of SARS-COV-2 was completely or partially resistant to neutralization by all nine clinically approved monoclonal antibodies tested.

Delphine Planas
Nell Saunders
Olivier Schwartz
Research23 Dec 2021
Nature

Volume: 602, P: 671-675
Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry

Here, Claireaux et al. show that people who naturally control HIV infection express lower levels of the viral co-receptor CCR5 in specific CD4⁺ T cells, and that this results from mutations or receptor internalization by CD4⁺ T cell-produced chemokines.

Mathieu Claireaux
Rémy Robinot
Lisa A. Chakrabarti
ResearchOpen Access26 Jan 2022
Nature Communications

Volume: 13, P: 1-19

Search

Filter By:

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry

Search

Quick links